Sen-Jam Pharmaceutical, an innovative life sciences company, announced on Friday that it has started enrolling patients into its phase two Clinical Trial for a potential oral COVID therapeutic in Nepal.

The company has also collaborated with KVK Tech that will offer access to Formulation and Chemistry, Manufacturing & Controls (CMC) for its COVID-19 therapeutic.

SJP-002C, Sen-Jam Pharmaceutical's investigational therapeutic for the treatment of COVID-19, is now enrolling patients for the clinical trial under a co-development agreement with Duke-NUS and Duke University School of Medicine.

Dr Alexander T Limkakeng Jr, MD, MHSc, FACEP, Professor, vice chief of Research and director, Acute Care Research at Duke Emergency Medicine, said, 'The study design has several unique features, including using a combination therapy that is widely available as an approved drug in countries around the world; has a known safety profile and well-understood mechanism of action of its individual components; has been studied in other viral illnesses; and could have complementary effects, with one agent potentially reducing the known side effects of the other.'